Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1

Conditions

Neoplasms 2Small Cell Lung Carcinoma 1Leukemia, Myeloid, Acute 1Leukemia 1Carcinoma, Small Cell 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × GSK2879552 × Clear all
NCT02034123 2019-12-06

Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma

GlaxoSmithKline

Phase 1 Terminated
29 enrolled 34 charts
Thoracic

Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT02177812 2019-06-28

A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML)

GlaxoSmithKline

Phase 1 Terminated
41 enrolled 34 charts
Other hematologic neoplasm

Leukemia, Neoplasms, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡